Switch theme
Sign up to access all valuation multiples
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. Its Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
1948
1.4K+
LTM Revenue $249M
Last FY EBITDA $38.8M
$307M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abbott Laboratories (Pakistan) has a last 12-month revenue (LTM) of $249M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Abbott Laboratories (Pakistan) achieved revenue of $242M and an EBITDA of $38.8M.
Abbott Laboratories (Pakistan) expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abbott Laboratories (Pakistan) valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $249M | XXX | $242M | XXX | XXX | XXX |
| Gross Profit | $77.0M | XXX | $70.1M | XXX | XXX | XXX |
| Gross Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $38.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 16% | XXX | XXX | XXX |
| EBIT | $38.6M | XXX | $30.2M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $22.5M | XXX | $18.6M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Abbott Laboratories (Pakistan)'s stock price is PKR 949 (or $3).
Abbott Laboratories (Pakistan) has current market cap of PKR 92.9B (or $330M), and EV of PKR 86.4B (or $307M).
See Abbott Laboratories (Pakistan) trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $307M | $330M | XXX | XXX | XXX | XXX | $0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Abbott Laboratories (Pakistan) has market cap of $330M and EV of $307M.
Abbott Laboratories (Pakistan)'s trades at 1.3x EV/Revenue multiple, and 7.9x EV/EBITDA.
Equity research analysts estimate Abbott Laboratories (Pakistan)'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abbott Laboratories (Pakistan) has a P/E ratio of 14.6x.
See valuation multiples for Abbott Laboratories (Pakistan) and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $330M | XXX | $330M | XXX | XXX | XXX |
| EV (current) | $307M | XXX | $307M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 8.0x | XXX | 10.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.6x | XXX | 17.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 52.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbbott Laboratories (Pakistan)'s last 12 month revenue growth is 7%
Abbott Laboratories (Pakistan)'s revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $28K for the same period.
Abbott Laboratories (Pakistan)'s rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abbott Laboratories (Pakistan)'s rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abbott Laboratories (Pakistan) and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abbott Laboratories (Pakistan) acquired XXX companies to date.
Last acquisition by Abbott Laboratories (Pakistan) was XXXXXXXX, XXXXX XXXXX XXXXXX . Abbott Laboratories (Pakistan) acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abbott Laboratories (Pakistan) founded? | Abbott Laboratories (Pakistan) was founded in 1948. |
| Where is Abbott Laboratories (Pakistan) headquartered? | Abbott Laboratories (Pakistan) is headquartered in Pakistan. |
| How many employees does Abbott Laboratories (Pakistan) have? | As of today, Abbott Laboratories (Pakistan) has 1.4K+ employees. |
| Is Abbott Laboratories (Pakistan) publicy listed? | Yes, Abbott Laboratories (Pakistan) is a public company listed on KAR. |
| What is the stock symbol of Abbott Laboratories (Pakistan)? | Abbott Laboratories (Pakistan) trades under ABOT ticker. |
| When did Abbott Laboratories (Pakistan) go public? | Abbott Laboratories (Pakistan) went public in 1982. |
| Who are competitors of Abbott Laboratories (Pakistan)? | Similar companies to Abbott Laboratories (Pakistan) include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Abbott Laboratories (Pakistan)? | Abbott Laboratories (Pakistan)'s current market cap is $330M |
| What is the current revenue of Abbott Laboratories (Pakistan)? | Abbott Laboratories (Pakistan)'s last 12 months revenue is $249M. |
| What is the current revenue growth of Abbott Laboratories (Pakistan)? | Abbott Laboratories (Pakistan) revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Abbott Laboratories (Pakistan)? | Current revenue multiple of Abbott Laboratories (Pakistan) is 1.2x. |
| Is Abbott Laboratories (Pakistan) profitable? | Yes, Abbott Laboratories (Pakistan) is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
